Brought to you by 
Zoticon gets rights to Lorus's Virulizin
09 Nov 2021
Executive Summary
Drug in-licenser and life sciences investor Zoticon Bioventures has licensed exclusive multi-territorial rights to Lorus Therapeutics' Virulizin, an immunotherapeutic that has received orphan drug and fast track status designations from the FDA and EMEA for various cancer indications including pancreatic.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zoticon gets rights to Lorus's Virulizin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice